ALPHAMAB ONCOLOGY financial statements, including revenue, expenses, profit, and loss
The total revenue of 9966 for the last semiannual is 88.92 M HKD, and it's 42.38% lower compared to the previous semiannual. The net income of H2 23 is -184.45 M HKD.